SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Novel ethical and policy issues in psychiatric uses of psychedelic substances
12 references·0 citing·44 second hop
Novel ethical and policy issues in psychiatric uses of psychedelic substances (2022)Novel ethical and policy issues in psychi…The Rapid Rise in Investment in Psychedelics—Cart Before the Horse (2022)The Rapid Rise in Investment …Trial of Psilocybin versus Escitalopram for Depression (2021)Trial of Psilocybin versus Es…MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (2021)MDMA-assisted therapy for sev…Psychedelics in Psychiatry—Keeping the Renaissance From Going Off the Rails (2020)Psychedelics in Psychiatry—Ke…Psychedelics and Psychedelic-Assisted Psychotherapy (2020)Psychedelics and Psychedelic-…Psychedelic medicine: safety and ethical concerns (2020)Psychedelic medicine: safety …Ethics and ego dissolution: the case of psilocybin (2020)Ethics and ego dissolution: t…Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder (2020)Effects of Psilocybin-Assiste…The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act (2018)The abuse potential of medica…Psychedelics: Where we are now, why we got here, what we must do (2018)Psychedelics: Where we are no…Effects of Schedule I drug laws on neuroscience research and treatment innovation (2013)Effects of Schedule I drug la…Human hallucinogen research: guidelines for safety (2008)Human hallucinogen research: …Hallucinogens (2004)Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance (2006)Power failure: why small sample size undermines the reliability of neuroscience (2013)LSD enhances suggestibility in healthy volunteers (2014)Blinding and expectancy confounds in psychedelic randomized controlled trials (2021)Adverse effects of psychedelics: From anecdotes and misinformation to systematic science (2022)Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer (2010)Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects (2011)DSM‐IV‐TR: Diagnostic and Statistical Manual of Mental Disorders (2013)Psilocybin with psychological support for treatment-resistant depression: six-month follow-up (2017)The world health report 2001 - Mental health: new understanding, new hope (2001)Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century (2015)Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial (2016)Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame (2019)A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses (2020)The acute effects of classic psychedelics on memory in humans (2021)Diagnostic and Statistical Manual of Mental Disorders (2013)Psychedelics (2016)Cessation and reduction in alcohol consumption and misuse after psychedelic use (2019)Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study (2020)Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial (2016)The Critical Relationship Between Anxiety and Depression (2020)Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up (2022)Towards an understanding of psychedelic-induced neuroplasticity (2022)An Introduction to the Five‐Factor Model and Its Applications (1992)A Psychobiological Model of Temperament and Character (1993)Diagnostic and Statistical Manual of Mental Disorders(DSM) (2008)Racial Justice Requires Ending the War on Drugs (2021)Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default (2022)Transformative experience and informed consent to psychedelic-assisted psychotherapy (2023)A RATING SCALE FOR DEPRESSION (1960)Manual for the State-Trait Anxiety Inventory (1970)The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults (2011)Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo (2021)Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder (2022)Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (2022)Posttraumatic Stress Disorder in the National Comorbidity Survey (1995)The Clinician-Administered PTSD Scale for DSM–5 (CAPS-5): Development and initial psychometric evaluation in military veterans. (2017)MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (2023)Psychedelics reopen the social reward learning critical period (2023)Psychedelic perceptions: mental health service user attitudes to psilocybin therapy (2021)Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research (2022)Expectancy in placebo-controlled trials of psychedelics: if so, so what? (2022)Single-Dose Psilocybin Treatment for Major Depressive Disorder (2023)
this work references cited by second hop

References

  • 2021Trial of Psilocybin versus Escitalopram for Depression1,386 cited
  • 2020Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder1,296 cited
  • 2008Human hallucinogen research: guidelines for safety1,201 cited
  • 2021MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study996 cited
  • 2020Psychedelics and Psychedelic-Assisted Psychotherapy649 cited
  • 2018The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act353 cited
  • 2013Effects of Schedule I drug laws on neuroscience research and treatment innovation338 cited
  • 2018Psychedelics: Where we are now, why we got here, what we must do187 cited
  • 2020Ethics and ego dissolution: the case of psilocybin144 cited
  • 2020Psychedelics in Psychiatry—Keeping the Renaissance From Going Off the Rails108 cited
  • 2020Psychedelic medicine: safety and ethical concerns101 cited
  • 2022The Rapid Rise in Investment in Psychedelics—Cart Before the Horse70 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work